Quince Therapeutics, Inc. (QNCX) Research
Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations. The company, previously known as Cortexyme, Inc., officially rebranded as Quince Therapeutics, Inc. in August 2022. Established in 2012, Quince Therapeutics is headquartered in South San Francisco, California.
Market snapshot
- Symbol
- QNCX
- Price
- $0.95
- Day change
- +4.66%
- Market cap
- $5.3M
- P/E ratio
- -0.14x
- 52-week range
- 0.79-45.5
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
Peer companies
Recent insider activity
- Lamond David — A-Award (2700 shares) on 2026-06-11
- Senner Christopher J. — A-Award (2700 shares) on 2026-06-11
- Roberts Brigette — A-Award (6837319 shares) on 2026-05-18
- Roberts Brigette — A-Award (2070107 shares) on 2026-05-18
- Roberts Brigette — A-Award (362092 shares) on 2026-05-18
Open Quince Therapeutics, Inc. (QNCX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.